Immune Checkpoints & Counterpoints: Toward a More Precise, Pro-Active Approach to Immune Modulation in Solid Tumors

Sant P. Chawla, MD

Counterpoint Biomedica LLC & The Sarcoma Oncology Center Santa Monica CA 90403

7th International Conference on Drug Discovery & Therapy
XC-Targeting, an Enabling Platform
Validation of Clinical Utility and Effectiveness

Targeted Clinical Retrovectors:
- Over 270 patients treated, >3,000 total infusions
- Demonstrated to be safe and well tolerated
- Cancers treated: Pancreas, soft tissue sarcoma, osteosarcoma, breast, lung, liver, kidney, prostate, larynx, colon, melanoma

Targeted Onco-Aptamers (mAb-Tropins):
- mAb-Tropin Design and Selection
- Preclinical Validation in Animals
- GMP Production and Formulation
- IND Development and FDA Approval
- Phase I/II Clinical Trials (Checkpoint mAbs)

Counterpoint’s founders previously developed Rexin-G and Reximmune-C, the first and only tumor-targeted gene expression vectors to be fully validated in the clinic.
The Clinical Problem: Systemic Biodistribution and Dose-Limiting Toxicities

The clinical toxicities of many biologic and chemotherapeutic agents is a result of the non-specific nature of drug distribution, which affects / damages normal tissues and organs.

- Chemotherapies and Biologics are distributed widely to both target and non-target organs, requiring high plasma levels to be effective.

- Immune Checkpoint Inhibitors (mAbs) produce a range of immune-related adverse events (irAEs).

- Systemic Delivery of Immune-stimulating Cytokines (GM-CSF, II-2, and INF-alpha) is associated with significant systemic toxicities.
The Clinical Solution:
More “Active” and Efficient Targeting of Drug Delivery

- **Passive Delivery Systems**—drug accumulations in the areas around tumors with leaky vasculature (EPR effects)—e.g. Nab-paclitaxel.
  - The majority (>95%) of passively administered cancer Drugs are known to accumulate primarily in other organs, in particular the liver, spleen, and lungs.

- **Active (or “Targeted”) Delivery** — provides the advantages of higher concentrations in tumors and lower systemic exposures, resulting in less systemic side effects and irAEs.
  - Active drug delivery is orders of magnitude more efficient than passive EPR effects, overcoming vast dilutions in the circulation while seeking-out and accumulating to high levels in tumor compartments.
  - Lower drug doses avoid the issues of dose-limiting toxicities and treatment-limiting toxicities — thus enhancing the treatment duration, natural immune responses, and ultimately tumor control.
Active Tumor Targeting: Targeting the Tumor Microenvironment

Exposure of Collagenous (XC-) Proteins is a HistoPathological Feature of all Invasive Cancers

Abnormal Tumor Microenvironment:

Collagenous XC-Proteins in a Human Tumor Biopsy are Stained Bright Blue by the Trichrome-stain

Tumor cells (t) immersed in a sea of exposed collagenous (XC-) proteins:

XC-Proteins exposed by tumor invasion, stroma formation, & angiogenesis.
von Willebrand Factor (vWF) is an important “targeting” protein involved in blood clotting and wound healing.

Naturally guides circulating platelets to injured and diseased tissues by seeking-out abnormal XC-proteins.

XC-Targeting: the surveillance function provides a molecular mechanism for the development of tumor-targeted drug delivery.
Rexin-G, XC-Targeted Retroviral Vector: First Targeted, Injectable Gene Delivery

Molecular Components of Tumor-Targeted Rexin-G

**Therapeutic Payload (Bioactive Construct)**
- Killer gene provides broad-spectrum activity

**Vector Design Engineering**
- Stealth vector enables repeated i.v. infusions

**Active (XC-) Tumor-Targeting**
- Tumor-targeting seeks out cancerous lesions
XC-Targeted Rexin-G: Seeks-out & Accumulates-in Human Tumors

Accumulation of Rexin-G vector particles seen in a metastatic liver lesion

*Treatment preceding surgery enabled direct visualization of histology*

Immunohistochemical staining for Rexin-G\textsuperscript{env} protein shows the XC-targeting-dependent accumulation of vector in:

- Tumor ECM (A)
- Tumor cells (C,D), and
- Tumor vasculature (E)
- Versus IHC Control (B)
Studies of XC-Targeted Rexin-G: Safety and Efficacy Proven in Clinical Trials

Clinical: Rexin-G as Monotherapy in Chemotherapy-resistant Cancers:

Phase I/II Study – all sarcomas*
Phase I/II Study – pancreas cancers*
Phase II Study – osteosarcoma*

RESULTS: Rexin-G® exhibits an outstanding safety record (with no DLT); dose-dependent single-agent efficacy; gains in tumor control, progression-free survival (PFS), and overall survival (OS).

• FDA grants Orphan Drug*: Osteosarcoma, STS, and Pancreatic Cancer

Rexin-G Improves Survival

Dose-Dependent Survival Benefits: The Gold Standard for Objective Responses
XC-Targeted Reximmune-C: Tumor-Targeted GM-CSF Expression Vector

The GeneVieve Protocol: Two-Stage Cancer Immunotherapy

Rexin-G (Cytocidal Gene) followed by Reximmune-C (Cytokine GM-CSF Gene provides vaccination in situ).

- **Rexin-G** is a tumor-targeted retroviral vector bearing a cytocidal Cyclin G1 construct, utilized to kill the tumor cells and expose neoantigens.

- **Reximmune-C** is a tumor-targeted retroviral expression vector bearing a GM-CSF gene, utilized to recruit the patient’s immune cells into the tumor microenvironment and to evoke tumor recognition and anti-tumor immunity.

(Killer T cells) Tumor-targeted Injectable Vector

 Gene Delivery  Residual Tumor
The residual tumor was resected two days after infusion of Rexin-G and Reximmune C. (A) H&E: areas of tumor necrosis with tumor infiltrating lymphocytes (TILs); (B) CEA+ tumor cells, (C) immunoreactive GM-CSF transgene (reddish-brown staining material) in a necrotic tumor, (D) MPO staining granulocytes; (E-G) CD4+, CD8+ and CD20+ TILs, indicating effective recruitment of patient’s tumor infiltrating lymphocytes into the residual tumor.
The Genevieve Protocol: **Rexin-G** Treatment followed by Tumor-Targeted **Reximmune-C** (i.v.)

Combined Effects of Rexin-G plus Reximmune-C

Progressive tumor regression was observed in serial bone scans obtained over 20 months following treatment initiation with Rexin-G to control tumor growth, followed by the Reximmune-C to stimulate a local immune response.

Regression of Skeletal Metastases in a Patient with Chemo-Resistant Ductal Carcinoma of Breast

![Regression of Skeletal Metastases](image)

A. Anterior and Posterior images before treatment on 07.01.2008
B. Anterior and Posterior images after Rexin-G on 01.26.2009
C. Anterior and Posterior images after GeneVieve on 03.02.2010
CONCLUSIONS:

✓ Tumor-Targeted vectors (Rexin-G and Reximmune-C) are well-tolerated with no dose-limiting or organ-related toxicity.

✓ Rexin-G controls tumor growth and may improve progression-free survival (PFS) and overall survival (OS) in chemo-resistant cancers (86% one year survival rate).

✓ Reximmune-C provides an opportunity for local stimulation of tumor immune responses.
Counterpoint’s founders previously developed Rexin-G and Reximmune-C, the first and only tumor-targeted gene expression vectors to be fully validated in the clinic.

XC-Targeting, an Enabling Platform
Validation of Clinical Utility and Effectiveness

Targeted Clinical Retrovectors:
- Over 270 patients treated, >3,000 total infusions
- Demonstrated to be safe and well tolerated
- Cancers treated: Pancreatic, breast, lung, kidney, prostate, laryngeal, colon, soft tissue sarcoma, osteosarcoma, Ewing’s sarcoma, melanoma

Targeting Onco-Aptamers (mAb-Tropins):
- mAb-Tropin Design and Selection
- Preclinical Validation in Animals
- GMP Production and Formulation
- IND Development and FDA Approval
- Phase I/II Clinical Trials (Checkpoint mAbs)
von Willebrand Factor (vWF) is an important “targeting” protein involved in blood clotting and wound healing.

Naturally guides circulating platelets to injured and diseased tissues by seeking-out abnormal XC-proteins.

XC-Targeting: the surveillance function provides a molecular mechanism for the development of tumor-targeted drug delivery.

Molecular Engineering the XC-Binding Domain of vWF Provides the Basis for Tumor-Targeted Drug Delivery

Von Willebrand Factor vWF binds and targets platelets to sites of injury by seeking out exposed collagens (XC-Proteins).

A Significant Injury Exposes Collagens

vWF Seeks-Out and Binds to XC-Proteins

Platelets (Hemostasis)

vWF-Targeted Platelet Aggregation at Exposed Collagens
The Counterpoint Approach: Onco-Aptamers Bifunctional Polypeptides Provide “Active” Drug Delivery

**XC-Targeted Drug Cargos:**
Chemotherapeutic Drugs, Small Molecules, mAbs, siRNAs, Nanoparticles.

**Drug Binding:**
High-affinity drug binding domains provide for strong non-covalent drug / aptamer interactions.
Note: the tumor-targeting platform does not require alterations in either the chemical composition or manufacturing of FDA-approved drug cargos.

**Primary Binding Domains of the Bifunctional Polypeptides**
1. Sequences that bind non-covalently to approved anti-cancer drugs (the cargo).
2. Proven tumor-targeting sequences that seek out and bind tightly to XC-proteins.
Lead XC-Targeted Onco-Aptamer Designs
Custom Engineered for Specific Classes of Drugs

A. Molecular Design of a Representative Onco-Aptamer

- N-Terminal Modification
- L1 – L3: Linker Sequences
- C-Terminal Modification

Drug-Binding Domain

XC-Targeting Domain

The linear polypeptide is small enough (≤ 50 aa) to be produced by chemical synthesis.

B. TAXOL-TROPIN: Active Taxane Targeting

- Drug Binding
- Tumor Targeting

- Non-Covalent Interactions
- Paclitaxel (Taxol)
- XC-Proteins

C. mAb-TROPIN: Active Antibody Targeting

- Drug Binding
- Tumor Targeting

- Therapeutic Antibodies
- XC-Proteins
Bifunctional tumor-targeting polypeptides
- XC-binding domain concentrates drug at the tumor sites
- XC-targeting is based on a clinically proven technology

Non-covalent drug-binding characteristics
- No modifications of the approved drug manufacturing required

Protease-resistant designs
- Terminal D-amino acids or PEGylation prevent degradation

Onco-aptamers are typically less than 50 amino acids
- Chemical synthesis of onco-aptamers is feasible – with predictable economies-of-scale

Applicable to a broad range of therapeutic modalities
- Taxanes, small molecules, mAbs, RNAis, nanoparticles
Checkpoints and Counterpoints: Mitigating “irAEs” with Pro-active Tumor Targeting

- **Monoclonal antibodies** (mAbs) are now well established as “targeted therapies” for a wide variety of malignancies; however, there are still problems with systemic biodistribution, target selectivity, poor tumor penetration, and untoward toxicities, which limit clinical utility.

- **Monoclonal antibodies** are typically considered to be safer than cytotoxic agents, but Immune Checkpoint Inhibitors bring a new toxicity profile.

- **Immune Checkpoint Inhibitors**, designed to activate anti-tumor T cell responses, offer a promising avenue for immunotherapy; however the systemic biodistribution of these potent mAbs introduces autoimmune disorders and serious **immune-related Adverse Events** (irAEs).

- **Tumor targeted onco-aptamers** are designed to compartmentalize the T cell response to enhance efficacy and reduce immune-related reactions.
Preclinical Validation *In Vitro* and *In Vivo*
Stringent Aptamer Binding Studies—Confirmed in Animals

**In Vitro Binding / Targeting:**
Agarose Affinity Chromatography (in layers) Model Tumor Tissues

High-affinity binding of onco-aptamers to the **Fluorescent Cargo** and to **XC-Proteins** is demonstrated in this in vitro simulation of tumor targeting (*A*, bright field), using layers of blank-agarose & collagen-agarose (as a moldel for tumors). Note: the aptamer-dependent band of intense fluorescence (*B*) shows XC-targeted drug delivery.

**Tumor-Targeting in Mice:**
The stringent binding studies translate into demonstrations of active tumor-targeting in vivo (*C*).
mAb-Tropins Bind the Fc Region of IgGs
Binding of Whole IgGs versus F(Ab’)2 Fragments

**XC-Agarose Binding Studies**

- **FITC-labeled IgGs vs F(Ab’)2 fragments** confirm the mAb-Tropin binding sites are in the Fc region of the IgG molecule.

- The deduced Fc binding site is far removed from IgG antigen-binding domains & receptor-mediated functions.
**mAb-Tropin^{277}: Proof-of-Concept In Vivo**

Targeted Delivery of FITC-IgGs to Tumors in Mice

### Efficient Binding in Vitro

#### Binding Assay In Vitro

XC-Agarose Chromatography

- **Pass-Through**
- **Retentates**

#### Binding Concentration

- **0**
- **25**
- **50**
- **75**
- **100 ug**

### Active Targeting in Cancer Model

#### Proof-of-Concept In Vivo

Nude Mouse Cancer Model

<table>
<thead>
<tr>
<th>Tumors:</th>
<th>Bright Field</th>
<th>Fluorescence</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>IgGFITC Only</td>
<td><img src="image1.png" alt="Image" /></td>
</tr>
<tr>
<td>2</td>
<td>IgGFITC     + mAb-T 277</td>
<td><img src="image2.png" alt="Image" /></td>
</tr>
<tr>
<td>3</td>
<td>Control Untreated</td>
<td><img src="image3.png" alt="Image" /></td>
</tr>
</tbody>
</table>

- Passive Delivery
- Active Delivery
- Background Fluorescence
**mAb-Tropin**$_{277}$: Clinical Development

“Pro-Active” Targeting of Immune Checkpoint Inhibitors

---

**Planned Phase 1/2 Study**

tumor-targeted immune checkpoint inhibitor(s)

**Clinical Indications:** Advanced Sarcoma, Melanoma, and NSLC

**Aptamer Dose Escalation:** 4

Dose Levels spanning a 1:1 molar ratio of mAb-Tropin to mAb/IgG.

**Study Aims:** Improved Safety & Efficacy of the lower dose mAb deployed with active targeting. (~1/2 the standard dose of mAb).

**Expected Results:** Confirmation of mAb-Tropin Safety, followed by Aptamer-dependent Efficacy with increasing Apt/IgG ratios.
Executive Officers of the Company
Expertise in R&D, Clinical Trials, INDs, and IP Development

Dr. Sant P. Chawla, M.D., Founder, President & Chief Medical Officer — Diplomate, American Board of Medical Oncology
A pioneering physician whose work in sarcoma oncology has brought him accolades and recognition as one of the world’s foremost experts of sarcomas & sarcoma therapy, with extensive experience in clinical trials.

Dr. Frederick L. Hall, Ph.D., Founder & Chief Executive Officer
An established leader in the field of cell cycle control, oncogene discovery, and genetic medicine. Founder, Former President, CEO, and CSO of Epeius Biotechnologies Corp., Dr. Hall served for 12 years as a Research Director on the faculty of the USC Schools of Medicine and Pharmacy, where he was a co-inventor of the tumor-targeting technology.

Dr. Erlinda M. Gordon, M.D., Founder & Chief Operating Officer — Diplomate, American Board of Pediatric Hematology/Oncology
Considered to be among the most accomplished physician-scientists in the field of cancer gene therapy. Founder, Former COO, CMO and Chairman of the Board of Epeius Biotechnologies Corp., Dr. Gordon served for 20 years on the faculty of the University of Southern California School of Medicine, and is co-inventor of the tumor-targeting technology.
Thank You

Sant P. Chawla, M.D., FRACP
COUNTERPOINT BIOMEDICA LLC
THE SARCOMA ONCOLOGY CENTER
2811 Wilshire Blvd, Suite 414
Santa Monica, CA 90403
santchawla@sarcomaoncology.com